TITLE

Trypanososma brucei rhodesiense Sleeping Sickness, Uganda

AUTHOR(S)
Berrang-Ford, Lea; Wamboga, Charles; Kakembo, Abbas S. L.
PUB. DATE
October 2012
SOURCE
Emerging Infectious Diseases;Oct2012, Vol. 18 Issue 10, p1686
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a study which examined patients diagnosed with human African trypanosomiasis (HAT) in Uganda. The total number of Trypanosoma brucei rhodesiense HAT cases in the country over a 10-year period is 140. Results of the study showed that there is a tendency among patients in Stamp Out Sleeping Sickness (SOS) districts to report cases in late stages of the disease. It also found higher mortality rates in patients with late-stage cases.
ACCESSION #
80919183

 

Related Articles

  • Human African Trypanosomiasis in the Democratic Republic of the Congo: A Looming Emergency? Hasker, Epco; Lutumba, Pascal; Chappuis, François; Kande, Victor; Potet, Julien; De Weggheleire, Anja; Kambo, Charles; Depoortere, Evelyn; Pécoul, Bernard; Boelaert, Marleen // PLoS Neglected Tropical Diseases;Dec2012, Vol. 6 Issue 12, p1 

    The author discusses the prevalence of Human African Trypanosomiasis (HAT) in the Democratic Republic of Congo (DRC). The author states that HAT is also known as sleeping sickness which is a parasitic disease which is fatal if left untreated. He notes that DRC is the worst affect country of HAT....

  • Gambiense sleeping sickness: re-emerging and soon untreatable? Van Nieuwenhove, Simon // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1283 

    Editorial. Comments on the return of sleeping sickness caused by Trypanosoma brucei gambiense. Deterioration and disruption of control activities; Problems on the implementation of active case detection and successful treatment; Gap between scientific progress and the implementation of...

  • Effectiveness of a 10-Day Melarsoprol Schedule for the Treatment of Late-Stage Human African Trypanosomiasis: Confirmation from a Multinational Study (IMPAMEL II). Schmid, Caecilia; Richer, Michaleen; Bilenqe, Constantin Miaka Mia; Josenando, Théophile; Chappuis, Francois; Manthelot, Claude R.; Nanqouma, Auquste; Doua, Félix; Asumu, Pedro N.; Simarro, Pere P.; Burn, Christian // Journal of Infectious Diseases;6/1/2005, Vol. 191 Issue 11, p1922 

    Background. Treatment of late-stage human African trypanosomiasis (HAT) with melarsoprol can be improved by shortening the regimen. A previous trial demonstrated the safety and efficacy of a 10-day treatment schedule. We demonstrate the effectiveness of this schedule in a noncontrolled,...

  • Revisiting the Immune Trypanolysis Test to Optimise Epidemiological Surveillance and Control of Sleeping Sickness in West Africa. Jamonneau, Vincent; Bucheton, Bruno; Kaboré, Jacques; Ilboudo, Hamidou; Camara, Oumou; Courtin, Fabrice; Solano, Philippe; Kaba, Dramane; Kambire, Roger; Lingue, Kouakou; Camara, Mamadou; Baelmans, Rudy; Lejon, Veerle; Büscher, Philippe // PLoS Neglected Tropical Diseases;Dec2010, Vol. 4 Issue 12, p1 

    Background: Because of its high sensitivity and its ease of use in the field, the card agglutination test for trypanosomiasis (CATT) is widely used for mass screening of sleeping sickness. However, the CATT exhibits false-positive results (i) raising the question of whether CATT-positive...

  • Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Pepin, Jacques; Khonde, Nzambi // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1284 

    Compares the effectiveness of 7 days of intravenous eflornithine with the standard 14-day regimen in the treatment of late-stage Trypanosoma brucei gambiense trypanosomiasis. Use of a randomized controlled trial; Death of some patients during treatment; Difference in response to treatment...

  • Sleeping bug: scientists identify drug resistance mechanism.  // Africa Health;Mar2012, Vol. 34 Issue 3, p12 

    The article focuses on the study conducted by the researchers in Greta Britain, which reveals several ways by which parasite Trypanosoma brucei can resist drugs used in treating sleeping sickness.

  • New Clues to Sleeping Sickness.  // JAMA: Journal of the American Medical Association;1/2/2013, Vol. 309 Issue 1, p20 

    The article informs that a new research conducted by the scientists of Germany, Sweden and the U.S. has explained the structure of a key enzyme named "Trypanosoma brucei cysteine protease cathepsin B," (TbCatB) from the parasite that causes African trypanosomiasis or sleeping sickness.

  • Estimates of the duration of the early and late stage of gambiense sleeping sickness. Checchi, Francesco; Filipe, João A. N.; Haydon, Daniel T.; Chandramohan, Daniel; Chappuis, François // BMC Infectious Diseases;2008, Vol. 8 Issue 1, Special section p1 

    Background: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to predicting the impact of screening on transmission....

  • Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda. Fèvre, Eric M.; Odiit, Martin; Coleman, Paul G.; Woolhouse, Mark E. J.; Welburn, Susan C. // BMC Public Health;2008, Vol. 8 Issue 1, p96 

    Background: Zoonotic sleeping sickness, or HAT (Human African Trypanosomiasis), caused by infection with Trypanosoma brucei rhodesiense, is an under-reported and neglected tropical disease. Previous assessments of the disease burden expressed as Disability-Adjusted Life Years (DALYs) for this...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics